Fig. 5: LPC-mediated suppression of GRASP65 expression and consequent effects on cognitive and motor function in mice. | npj Parkinson's Disease

Fig. 5: LPC-mediated suppression of GRASP65 expression and consequent effects on cognitive and motor function in mice.

From: Lysophosphatidylcholine promoting α-Synuclein aggregation in Parkinson’s disease: disrupting GCase glycosylation and lysosomal α-Synuclein degradation

Fig. 5

a, b Analysis of GRASP65 expression levels in MES23.5 dopaminergic neurons via WB assay following intervention with varying doses of LPC (n = 3, Control vs LPC10: p = 0.0147, Control vs LPC15: p < 0.0001). c Fluorescence staining images depicting TH and GRASP65 in SNC dopaminergic neurons of C57 mice post-LPC (1 mg/mL) injection and MPTP modeling. d, e Quantification of immunofluorescence intensity for TH and GRASP65 (n = 3, TH: t = 4.433, p = 0.0114; GRASP65: t = 5.741, p = 0.0046). f Flowchart illustrating virus injection, LPC injection, and behavioral phenotype testing procedures. g Schematic representation of lenti-virus injection in the SNC region of C57 mice. h, i Time spent time in new arm for Control, LPC, GRASP65 knockdown (KD), and LPC + GRASP65 overexpression (OE) groups in the Y-maze experiment (n = 6, Control vs LPC: p < 0.0001, Control vs GRASP65 KD: p < 0.0001, LPC vs LPC + (GRASP65 OE): p < 0.0001).

Back to article page